您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8473 处方药 8099 非处方药 268 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 肾移植->肾移植
处方药:处方药
包装规格: 50毫克/片 100片/瓶
计价单位:
   
生产厂家英文名:
PROMETHEUS LABS
该药品相关信息网址1:
http://www.igenericdrugs.com/gd.cgi?notran=1&s=IMURAN&search=SEARCH
原产地英文商品名:
IMURAN 50 MG 100 Tablets
原产地英文药品名:
AZATHIOPRINE
中文参考商品译名:
依木兰 50毫克/片 100片/瓶
中文参考药品译名:
硫唑嘌呤片
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
organ transplant patients anti-rejection reactions
英文适应病症2:
severe rheumatoid arthritis
英文适应病症3:
systemic lupus erythematosus
临床试验期:

中文适应病症参考翻译1:
器官移植病人的抗排斥反应
中文适应病症参考翻译2:
风湿性关节炎
中文适应病症参考翻译3:
系统性红斑狼疮
药品信息:

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201411510341620.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文依木兰处方资料(仅供参考)

英文药名: Imuran (Azathioprine Tablets)

中文药名: 依木兰(硫唑嘌呤片)

别名:氮杂硫代嘌呤;咪唑巯嘌呤;依木兰;义美仁;硫唑嘌呤

外文名:Azathioprine,Imuran, AZP

药理作用

本药是6-硫基嘌呤的咪唑衍生物,为具有免疫抑制作用的抗代谢剂。可产生烷基化作用阻断SH组群,抑制核酸的生物合成,防止细胞的增生,并可引起DNA的损害。动物实验证实,本药可使胸腺、脾内DNA、RNA减少,影响DNA、RNA,以及蛋白质的合成,主要抑制T-淋巴细胞而影响免疫,所以可抑制迟发过敏反应,器官移植的排斥反应。本药的疗效需于治疗数周或数月后才出现。在上消化道内吸收较佳。血浆中的硫唑嘌呤及6-硫基嘌呤水平与本药的疗效及毒性无相互关系。 毒理研究

本药可致染色体异常,动物实验表明可致不同程度的胎儿异常,并具有明显的致畸性,不能排除本药对人体的致癌性。

适应症

本药与其它药物联合应用于器官移植病人的抗排斥反应,例如肾移植、心脏移植及肝移植,亦减少肾移植受者对皮质激素的需求。本药也可单独使用于严重的风湿性关节炎,系统性红斑狼疮,皮肌炎/多发性肌炎,自体免疫性慢性活动性肝炎,寻常天疱疮,结节性多动脉炎,自体免疫性溶血性贫血,慢性顽固自发性血小板减少性紫癜。 用法用量

*注射剂只有在无法口服时才由静脉给药,且当口服疗法可以耐受时即应停用。 器官移植

第1日给予5 mg/kg体重,口服或静注。维持剂量要根据临床需要和血液系统的耐受性而调整,通常为1-4 mg/kg体重/日。维持治疗应无限期地进行。因为如果治疗中断,就有排斥的危险。

其它疾病

开始剂量为1-3 mg/kg体重/日。应根据临床反应和血液学指标所示耐受程度而定。治疗效果明显时,应减少维持量至可保持此治疗效果的最低水平。如3个月内病人情况无改善,应考虑停用。所需维持量从1 mg/kg体重/日至3 mg/kg体重/日不等,取决于临床治疗需要和病人个体反应,包括血液学指标所示的耐受程度。 兼有肝和/或肾功能不全者,剂量酌减。老年人用药的副作用发生率较其他病人高,应采用推荐剂量范围的低限值。

*本药片剂不应被切开。

任何疑问,请遵医嘱!

不良反应

过敏反应:如全身不适、头晕、恶心、呕吐、腹泻、发热、寒战、肌痛、关节痛、肝功能异常和低血压。应立即停药和给予支持疗法,可使大部分病例恢复。 造血功能:可能产生剂量相关性、可逆性骨髓抑制,常见白细胞减少症,偶见贫血及血小板减少性紫癜。

感染:使用本药和肾上腺皮质激素的器官移植受者对病毒、真菌和细菌感染的易感性增加。

胃肠道反应:偶有恶心,餐后服药可缓解。罕见胰腺炎。

肺部反应:罕见可逆性肺炎。

禁忌症

对本药及6-疏基嘌呤过敏者禁用。

注意事项

在治疗的首8周内,至少每周检查1次全血象,包括血小板。如使用大剂量或病人有肝和/或肾功能不全时,血象检查的次数应该更多。此后每月或最少每3个月重复进行全血象的检查。 对肾和/或肝功能不全者,应使用推荐剂量的低限值及小心地监察血液学及肝肾功能。若出现肝或血液学毒性时,更应再减剂量。用药期间不要进行活疫苗的免疫接种。 孕妇及哺乳期妇女用药

临床上证明本药对胎儿有不良影响,只有对孕妇的益处大于对胎儿产生的危险时,才可考虑使用。本药可分泌入乳汁,故哺乳妇女慎用。

药物相互作用

别嘌呤醇可抑制巯基嘌呤(后者是硫唑嘌呤的活性代谢物)代谢成无活性产物,结果使巯基嘌呤的毒性增加,当二者必须同时服用时,硫唑嘌呤的剂量应该大大地减低,硫唑嘌呤可降低6-巯嘌呤的灭活率,6-巯嘌呤的灭活通过下列方式:酶的S-甲基化,与酶无关的氧化,或是被黄嘌呤氧化酶转变成硫尿酸盐等。硫唑嘌呤能与巯基化合物如谷胱甘肽起反应,在组织中缓缓释出6-巯嘌呤而起到前体药物的作用。

Imuran - Used for: Preventing kidney transplant rejection when used along with other medicines. It may also be used to reduce signs and symptoms of active rheumatoid arthritis. It may also be used for other conditions as determined by your doctor. Imuran is an antimetabolite. It works by decreasing the effects of certain cells in the body\'s immune system.

Imuran is used to prevent your body from rejecting a transplanted kidney. It is also used to treat symptoms of rheumatoid arthritis.

Imuran may also be used for purposes not listed in this medication guide.

Imuran is a chemotherapy drug, now rarely used for chemotherapy but more for immunosuppression in organ transplantation and autoimmune disease such as rheumatoid arthritis or inflammatory bowel disease or Crohn\'s disease. It is a pro-drug, converted in the body to the active metabolite 6-mercaptopurine. Imuran acts to inhibit purine synthesis necessary for the proliferation of cells, especially leukocytes and lymphocytes. It is a safe and effective drug used alone in certain autoimmune diseases, or in combination with other immunosuppressants in organ transplantation. Its most severe side effect is bone marrow suppression, and it should not be given in conjunction with purine analogues such as allopurinol. The enzyme thiopurine S-methyltransferase (TPMT) deactivates 6-mercaptopurine. Genetic polymorphisms of TPMT can lead to excessive drug toxicity, thus assay of serum TPMT may be useful to prevent this complication.

Indication: For use as an adjunct in the prevention of rejection in renal homotransplantation. Also for the management of severe, active rheumatoid arthritis unresponsive to rest, aspirin or other nonsteroidal anti-inflammatory drugs, or to agents in the class of which gold is an example.

Imuran is used on its own or together with other medicines to prevent the rejection of new organs after an organ transplant. Imuran is also used to treat certain autoimmune conditions where your body attacks its own cells or tissues, such as Crohn\'s disease, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE or lupus) and other autoimmune connective tissue disorders. Imuran belongs to a class of medicines known as immunosuppressants. Imuran is a drug that suppresses the immune system.

Imuran is used in organ transplantation and autoimmune disease. Some of the autoimmune diseases are rheumatoid arthritis, pemphigus, Inflammatory Bowel Disease (such as Crohn\'s disease and Ulcerative Colitis), multiple sclerosis, autoimmune hepatitis and restrictive lung disease. Imuran interferes with the synthesis of purines (adenine and guanine), which is required for DNA synthesis. Fast-growing cells, including T-cells and B-cells, are particularly affected by the inhibition of purine synthesis. It is a pro-drug, converted in the body to the active metabolites 6-mercaptopurine (6-MP) and 6-thioinosinic acid.

Treatment of patients who have received an organ transplant. Imuran has a significant therapeutic effect in a proportion of patients suffering from chronic active hepatitis, severe rheumatoid arthritis, systemic lupus erythematosus (SLE), dermatomyositis, pemphigus vulgaris, polyarteritis nodosa, acquired hemolytic anemia, idiopathic thrombocytopenic purpura and pyoderma gangrenosum. Imuran is used in conditions other than transplantation, the following are: Refractory to corticosteroids alone; controlled by corticosteroids in dosages producing or likely to produce severe side effects and the primary aim is to reduce the requirements of steroids; or corticosteroids are contraindicated. In pemphigus and rheumatoid arthritis, Imuran has been shown to have significant therapeutic activity when used without corticosteroids. In other indications or where local registration authority approval has not yet been given for a particular indication, the use of Imuran must be regarded as experimental. The risk associated with Imuran therapy should be considered against the severity of the patient\'s condition and the prospects of therapeutic benefit.

As an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. Imuran, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants eg, renal, cardiac and hepatic transplants; and to reduce the corticosteroid requirements of renal transplant recipients. Imuran, either alone or more usually in combination with corticosteroids and/or other drugs and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: Severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune hemolytic anemia, chronic refractory idiopathic thrombocytopenic purpura.

As an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. Imuran, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants eg, renal transplants, cardiac transplants and hepatic transplants; and to reduce the corticosteroid requirements of renal transplant recipients. Treatment of moderate to severe inflammatory bowel disease (IBD) (Crohn\'s disease or ulcerative colitis) in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy or in patients whose disease is refractory to other standard 1st-line therapy. Imuran, either alone or more usually in combination with corticosteroids and/or other drugs and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: Severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune hemolytic anemia, chronic refractory idiopathic thrombocytopenic purpura and relapsing remittent multiple sclerosis.

Imuran is indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation:

Imuran is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. Imuran, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants eg, renal, cardiac and hepatic transplants. It also reduces the corticosteroid requirements of renal transplant recipients. Imuran, either alone or more usually in combination with corticosteroid and/or other drugs and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: Severe rheumatoid arthritis, systematic lupus erythematosus, dermatomyositis and polymyositis, auto-immune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, auto-immune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.

Indications: transplant rejection Indications: transplant rejection, auto-immune disorders

Indications: prevention of rejection in renal homotransplantation, rheumatoid arthritis

Imuran is used with other medications to prevent rejection of kidney transplants. It is also used to treat severe rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain and swelling) when other medications and treatments have not helped. Imuran is in a class of medications called immunosuppressants. It works by weakening the body’s immune system so it will not attack the transplanted organ or the joints. Azathioprine is also used to treat ulcerative colitis (a condition in which sores develop in the intestine causing pain and diarrhea). Talk to your doctor about the possible risks of using this drug for your condition.

Indications: Renal transplantation.

Autoimmune diseases.

Severe rheumatoid arthritis unresponsive to other drugs.

Imuran is a drug that suppresses the immune system. Imuran is used in organ transplantation and autoimmune disease. Some of the autoimmune diseases are rheumatoid arthritis, pemphigus, Inflammatory Bowel Disease (such as Crohn's disease and Ulcerative Colitis), multiple sclerosis, autoimmune hepatitis and restrictive lung disease. Imuran interferes with the synthesis of purines (adenine and guanine), which is required for DNA synthesis. Fast-growing cells, including T-cells and B-cells, are particularly affected by the inhibition of purine synthesis. It is a pro-drug, converted in the body to the active metabolites 6-mercaptopurine (6-MP) and 6-thioinosinic acid.

更新日期: 2013-07-21
附件:
201411510341620.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com